Rotigotine for anxiety during wearing-off in Parkinson's disease with dementia

Alessandra Fanciulli, Francesca Assogna, Carlo Caltagirone, Gianfranco Spalletta, Francesco E. Pontieri

Research output: Contribution to journalArticlepeer-review


Background: Wearing-off (WO) refers to the exacerbation of motor and/or non-motor symptoms of Parkinson's disease at the end of dose of dopaminergic medications. Treatment of WO is based on modifying drug schedule, meal timetable and/or increasing dopamine replacement therapy. In advanced and/or demented patients, management of WO is often limited by scarce compliance and by cognitive, psychiatric and dysautonomic side-effects that may accompany increased dopaminergic stimulation. Methods: Here, we report 2 patients suffering from Parkinson's disease with dementia, who experienced anxiety as non-motor symptom of WO under stable levodopa therapy. In both cases, transdermal rotigotine (4 mg/day) was added to the original dopaminergic therapy. Results: Rotigotine proved beneficial on symptoms of anxiety in both patients, without worsening cognitive and behavioral symptoms. During the 9-month follow-up period, there was a slight improvement of motor impairment, with no worsening of drug-related dyskinesia. Conclusions: These preliminary results suggest that rotigotine at low dose might improve non-motor symptoms of WO in elderly patients suffering from Parkinson's disease with dementia, without raising major safety issues.

Original languageEnglish
Pages (from-to)601-603
Number of pages3
JournalAging clinical and experimental research
Issue number5
Publication statusPublished - Oct 2013


  • Anxiety
  • Dementia
  • Non-motor symptoms
  • Parkinson's disease
  • Rotigotine
  • Wearing off

ASJC Scopus subject areas

  • Ageing
  • Geriatrics and Gerontology


Dive into the research topics of 'Rotigotine for anxiety during wearing-off in Parkinson's disease with dementia'. Together they form a unique fingerprint.

Cite this